KDIGO 2023 CKD Guideline Available for Public Review |
|
KDIGO has updated the 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). The 2023 KDIGO CKD Guideline is available for public review through Monday, July 24. KDIGO invites you to review this guideline and share your candid comments and suggestions. KDIGO will prepare a final revised version for publication based on this feedback.
The KDIGO 2023 CKD Guideline and feedback surveys can be found on the KDIGO CKD Guideline Website. The feedback surveys are organized by chapter and special considerations, and comments may be submitted on one or all chapters. Please note that by agreeing to provide feedback on a KDIGO draft guideline document, you permit KDIGO to acknowledge your participation as a reviewer in the final publication.
The aim of the update to the CKD Guideline is to generate a useful resource that clearly and concisely addresses relevant questions with actionable recommendations based on a formal evidence review and consensus-based practice points to guide clinical practice. The 2023 CKD Guideline is co-chaired by Adeera Levin, MD (Canada), and Paul Stevens, MB (United Kingdom).
|
|
KDIGO CKD-MBD Controversies Scope of Work Available for
Public Review
|
|
The Scope of Work (SOW) for the KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Progress and Knowledge Gaps Towards Personalizing CKD-MBD Care Controversies Conference is available for public review through Friday, August 4.
The conference will take place in Madrid, Spain, from September 28 - October 1, 2023, and will be co-chaired by Markus Ketteler, MD (Germany) and Rosa Maria Affonso Moysés, MD (Brazil).
The conference will involve plenary lectures covering the key literature published since the 2017 CKD-MBD Guideline update. New emerging topics of interest will be presented with select controversial issues to be covered more in-depth in the breakout group sessions. The conference output will include the publication of a position statement that will help guide KDIGO and the nephrology community on the therapeutic management and future research in CKD-MBD.
|
|
KDIGO Announces Increased Focus on Cardiovascular and Kidney Disease Programs |
|
KDIGO recently announced an increased focus on cardio-kidney issues. Having completed a four-part Controversies Conference series on CVD and CKD issues, KDIGO will now develop guidelines on cardio-kidney topics. Several topics will be covered, starting with heart failure in CKD. KDIGO will hold a Heart Failure Controversies Conference in February 2024. That Conference will explore new developments and issues that can be covered by the guideline.
KDIGO Co-Chair Morgan Grams, MD (United States), said, “This is an exciting time for KDIGO and for all of us in nephrology. I am thrilled to facilitate the development and implementation of kidney guidelines and very much support our priority to provide guidance in cardiovascular disease, a core need in nephrology. The contributions by KDIGO and the enormous number of global volunteers are exceptionally important in our field and for our patients.” Read the full news release.
|
|
KDIGO at the ATC 2023 Congress and the 60th ERA Congress |
|
KDIGO was delighted to attend the 2023 ATC Congress in San Diego and see friends and colleagues in the transplant community.
In addition to a booth featuring a number of transplant resources, KDIGO took part in a patient panel dinner with a discussion moderated by Krista Lentine, MD, (United States), with patient panelists, Jullie Hoggan and Alex Flaxman. The panel addressed a wide range of important issues facing patient recipients with a kidney transplant. The dinner was supported by CareDx.
|
|
 |
Photos from the KDIGO Patient Panel Dinner at ATC 2023. Photo credit: Moderator, Krista Lentine. |
|
|
|
KDIGO ERA Session on the 2023 CKD Guideline |
|
|
|
KDIGO was thrilled to be back in Milan for the 60th ERA Annual Congress. KDIGO had two sessions on the congress program, including a review of the Diabetes in CKD Guideline and its application in Europe, and a sneak peek at the CKD Guideline Update. Please note: Some of the statements included in the session on the CKD Guideline Update have been updated in the CKD Guideline Public Review draft. Watch the CKD Guideline Update session from the 60th ERA Congress. |
|
ISN-KDIGO Webinar: Novel Anemia Therapies
Thursday, July 20, 5:00 PM CEST (11:00 AM EDT)
Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors
(HIF-PHIs) are a new class of oral drugs for the treatment of anemia in CKD patients. They demonstrate comparable efficacy to erythropoietin-stimulating agents (ESA) in anemia correction and maintenance. Despite expectations, they have not shown better outcomes compared to ESA.
This webinar, moderated by David Wheeler, MD (United Kingdom), and featuring speakers Volker Haase, MD (United States), and Lucia Del Vecchio, MD (Italy), will start from a clinical case and propose some points of reflection on which patients could be candidates for the use of this new class of drugs. Register for the ISN-KDIGO Webinar on Novel Anemia Therapies.
|
|
New KDIGO Podcast Series on Primary Care and CKD
KDIGO is pleased to release a new 4-episode series of the Conversations in Nephrology Podcast. The new series, hosted by Peter Lin, MD (Canada), focuses on primary care and CKD. You can listen to the latest episodes on all major podcast platforms and the KDIGO Podcast Website.
Conversations include:
- Early Detection of CKD with Lekha Tummalapalli, MD (United States)
- CKD Evaluation and Measurement with Magdalena Madero, MD (Mexico)
- Applying CKD Interventions with Joel Topf, MD (United States)
- Appropriate CKD Referral to Specialists with Ikechi Okpechi, MD (Canada)
|
|
|
|
KDIGO Presents: A CKD Patient Journey
This KDIGO video highlights the importance of early referral to a nephrologist to slow or prevent kidney disease progression, with particular emphasis on the significance of patient buy-in and self-management. John Ortiz, a patient with polycystic kidney disease, shares his journey from misdiagnosis, to a kidney transplant, to dialysis.
|
|
Optimization of RAASi Therapy Toolkit
Kidney diseases are intricately linked to increased morbidity with, and mortality from, other diseases and infections. An integrated approach to noncommunicable disease (NCD) prevention and management that recognizes the burden of kidney disease and concomitant co-morbidities is critical to ensure no disease is left behind.
The toolkit on the optimization of RAASi therapy and management of related complications consists of focused and practical infographics, serving as hands-on references for nephrologists, cardiologists, and other healthcare professionals involved in the multidisciplinary care of patients with cardio-renal complications. Check out the Optimization of RAASi Therapy Toolkit.
|
|
New KDOQI Commentary on 2021 KDIGO Clinical Practice Guideline for Glomerular Diseases
The National Kidney Foundation (NKF) and its Kidney Disease Outcomes Quality Initiative (KDOQI) recently announced the publication of the KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. This new comprehensive review, published in the American Journal of Kidney Disease (AJKD), finds generally broad agreement with the KDIGO guidelines. Read the full commentary.
|
|
About KDIGO
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve outcomes for people with kidney disease on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the people it serves.
|
|
|
|
|
|
|
